Monsenso has signed an agreement with Awakn Life Sciences to support the company's medical psychedelic treatments. Psychedelic-assisted therapy has emerged as a potential solution to this treatment vacuum. In the early 20th century, these substances were severely restricted and had a negative connotation.

However, a growing body of evidence and urgent unmet patient needs have led clinicians and regulators to consider them as a viable treatment option. In October 2021, Awakn Life Science commenced implementation of the Monsenso Digital Health Solution in its clinical practice to support patients throughout their treatment journey and to capture real-world data to inform clinicians' decision making for personalised patient support and management.